Schroder Investment Management Group’s Celldex Therapeutics CLDX Stock Holding History

Schroder Investment Management Group’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-48,099	Closed	-$1.26M	–	1156
2025 Q3	$1.26M	Hold	48,099	–	–	﹤0.01%	997
2025 Q2	$979K	Hold	48,099	–	–	﹤0.01%	995
2025 Q1	$959K	Hold	48,099	–	–	﹤0.01%	994
2024 Q4	$1.21M	Hold	48,099	–	–	﹤0.01%	993
2024 Q3	$1.6M	Hold	48,099	–	–	﹤0.01%	970
2024 Q2	$1.78M	Hold	48,099	–	–	﹤0.01%	944
2024 Q1	$2.02M	Hold	48,099	–	–	﹤0.01%	922
2023 Q4	$1.91M	Buy	+48,099	New	+$1.41M	﹤0.01%	917
2014 Q4	–	Sell	-1,500	Closed	-$292K	–	1364
2014 Q3	$292K	Hold	1,500	–	–	﹤0.01%	1143
2014 Q2	$367K	Hold	1,500	–	–	﹤0.01%	1093
2014 Q1	$398K	Hold	1,500	–	–	﹤0.01%	1101
2013 Q4	$545K	Hold	1,500	–	–	﹤0.01%	1102
2013 Q3	$797K	Buy	+1,500	New	+$514K	﹤0.01%	1044

Other funds holding CLDX

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Schroder Investment Management Group's CLDX Position: Q4 2025 in Review

Schroder Investment Management Group sold out of Celldex Therapeutics (CLDX) in Q4 2025, closing a stake of 48,099 shares — an estimated $1.26M sold.

Schroder Investment Management Group first reported a position in CLDX in Q3 2013 and held it in 13 quarters. The position peaked at $2.02M in Q1 2024. 185 funds tracked by Wall St. Rank hold CLDX as of Q4 2025.

Schroder Investment Management Group reported no remaining Celldex Therapeutics position as of Q4 2025 after selling out during the quarter.
Schroder Investment Management Group sold 48,099 Celldex Therapeutics shares in Q4 2025, an estimated $1.26M.
Schroder Investment Management Group first reported a position in Celldex Therapeutics in Q3 2013 and held it in 13 quarters.
Schroder Investment Management Group's Celldex Therapeutics position peaked at $2.02M in Q1 2024.
185 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2025.

Based on Schroder Investment Management Group's 13F filing for Q4 2025, filed 13 Feb 2026.